Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab for airway inflammation and epithelial immune response in COPD
2022-000179-38Phase 2Active
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of tezepelumab in chronic obstructive pulmonary disease (COPD), sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoint: Change in eosinophil cell counts in bronchial mucosa. Started Feb 2022; status: active.
02
Drugs
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2022-000179-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000179-38.